Early-stage breast cancer detection with a plasma cell-free RNA and AI-based liquid biopsy platform

Lee Schwartzberg¹, Mehran Karimzadeh¹, Amir Momen-Roknabadi¹, Taylor B. Cavazos¹, Nae-Chyun Chen¹, Jieyang Wang¹, Michael Multhaup¹, Jeremy Ku¹, Akshaya Krishnan¹, Martha Hernandez¹, Rose Hanna¹, Lisa Fish¹, Magdalena Gebala¹, Anna Hartwig¹, Hani Goodarzi², Helen Li¹, Fereydoun Hormozdiari³, Babak Behsaz¹, Babak Alipanahi¹

¹Exai Bio Inc., Palo Alto, CA; ²Arc Institute, Palo Alto, CA; ³University of California, Davis, CA, US

Disclosures:

Disclosures: LS, MK, AR, TBC, NC, JW, MM, JK, AK, MH, RH, LF, MG, AH, HL, and BB, are or were employees of Exai Bio. BA is a co-founder, stockholder, and full-time employee of Exai Bio. HG is a co-founder, stockholder, and advisor to Exai Bio. FH is an advisor to Exai Bio.

Early-stage breast cancer detection with a plasma cell-free RNA and AI-based liquid biopsy platform

Disclosures:

View the PDF >